Build **HepaIQ AI**, a $25K/year **Healthtech SaaS + edge AI + clinical workflow platform** that **deploys AI-driven HDV diagnostics, real-time patient monitoring, and automated treatment optimization** via **Roche cobas integration, wearable liver function sensors, and predictive analytics**. The platform would: (1) **Deploy ‘LiverSense’ wearables** ($300/unit): FDA-cleared continuous liver function monitors (e.g., transient elastography patches) with edge AI (Jetson Orin) to auto-detect HDV flare-ups (e.g., ‘Patient #XYZ: ALT spike—trigger HDV test’); (2) **Provide ‘HDV Quantify’**: Integrates with Roche cobas to auto-quantify HDV RNA and predict treatment response (e.g., ‘HDV RNA: 10^5 IU/mL—start bulevirtide’); (3) **Integrate with ‘EHR APIs’** (Epic, Cerner) to auto-generate FDA-cleared diagnostic reports (e.g., ‘FDA eCopy: 100% compliant—submit’); (4) **Offer ‘Treatment Optimizer’**: AI-driven bulevirtide/interferon dosing (e.g., ‘Bulevirtide: 2mg/day—90% viral suppression’); (5) **Include ‘Global HDV Registry’**: Monetizes de-identified patient data for pharma trials (e.g., ‘Your 500 patients = $250K/year’).

Hepatitis D (HDV) is the most severe form of viral hepatitis, leading to accelerated liver disease and hepatocellular carcinoma. Current diagnostics are manual, slow, and prone to errors, creating delays in treatment and poor patient outcomes. Clinicians lack real-time, scalable solutions to detect and quantify HDV RNA, especially in resource-limited settings. The financial cost of untreated HDV includes increased hospitalizations, liver transplants, and lost productivity, estimated at $3B+ annually in the EU and USA alone.